Investor Overview

FAST FACTS

OUR INVESTMENT CASE

Globally recognised specialty pharma company with exposure to emerging markets and emerging market fundamentals Strategically relevant and in-demand manufacturing capabilities Diverse product portfolio with strong brand equity supported by in-country commercial and sales employees Strong financial position following the reshaping of the business Committed management team aligned with shareholder interests A purpose-driven strategy with the promotion of access to medicine at its core

Globally recognised specialty pharma company with exposure to emerging markets and emerging market fundamentals

Commercial Pharmaceuticals revenue: CER

Emerging market growth > Developed market growthon a three-year compound annual growth rate (“CAGR”)

Strategically relevant and in-demand manufacturing capabilities

Diverse product portfolio with strong brand equity supported by in-country commercial and sales employees

Strong financial position following the reshaping of the business

Committed management team aligned with shareholder interests

A purpose-driven strategy with the promotion of access to medicine at its core

		Manufactured 225 million doses of COVID-19 vaccines and signed a 10-year agreement with Serum Institute promoting access to vaccines in Africa

		Supplied 180 medicines appearing on the Essential Medicines List to 60 low- and middle-income countries

		Consistent inclusion in the FTSE/JSE Responsible Investment index since 2016 and member of the FTSE4Good Index

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

Annual Results Presentation for the year ended 30 June 2022

PDF 3.3Mb

Interim Results Presentation for the six months ended 31 December 2021

PDF 3.3Mb

CAPITAL
DISTRIBUTIONS

All capital distributions to date

SHAREHOLDER
STATISTICS

Analysis of shareholders at 30 June 2021

CORPORATE INFORMATION

All corporate information and contact details

REGISTER FOR ALERTS

Register via Vault for alerts of SENS announcements, reports and event invitations.

CONTACT DETAILS

Investor Relations
+27 31 580 8600
InvestorRelations@aspenpharma.com

WEBCASTS

Click to view the webcast
of our Financial Results for
the year ended 30 June 2022
1 September 2022 | 08:30 CAT

Click to view the webcast recording
of our Financial Results for
the six months ended
31 December 2021

Click to view the webcast recording
of our Financial Results for
the year ended 30 June 2021

Click to view our
Investor Day webcast of
11 December 2020

INVESTOR CALENDAR

01
March 2023 Interim results: SENS announcement

02
March 2023 Interim results presentation: In-person & livestreamed

30
August 2023 Annual results: SENS announcement

31
August 2023 Annual results presentation: In-person & livestreamed

07
December 2023 Annual General Meeting

		Commercial Pharmaceuticals branded OTC portfolio covering 174 different product categories

		Commercial Pharmaceuticals branded prescription (“Rx”) portfolio covering 184 different product categories

		2 088 Commercial and sales employees in Emerging markets

		304 Commercial and sales employees in Developed markets

		Lowest net debt/EBITDA in five years, creates headroom for value accretive acquisitions

		The highest NHEPS in Aspen’s history (FY2022)

		Strategic investments in sterile capacity will support increased return on invested capital (“ROIC”)

		Decentralised in-country structures enable local teams to operate with entrepreneurial flair; creating value by applying local expertise

		17% Shareholding by executive management